Notice to Biotie shareholders on registration of merger

BIOTIE THERAPIES CORP. STOCK EXCHANGE NOTICE 5 October 2011 at 9:30 a.m.
(Helsinki time)

Notice to Biotie shareholders on registration of merger plan and documents
available for review

The Boards of Directors of Biotie Therapies Corp. ("Biotie" or the "Company")
and Newron Pharmaceuticals S.p.A. ("Newron"), have on 27 September 2011 signed a
merger plan (the "Merger Plan"), according to which Newron will merge into
Biotie and all of its all assets and liabilities will transfer to Biotie and the
shareholders of Newron will receive new Biotie shares and options and a
receivable intended to be used to pay the subscription price for Biotie shares
subscribed based on such options as merger consideration (the "Merger").

The Merger Plan has today been registered with the Finnish Trade Register. This
notice is the notice to the Company's shareholders pursuant to Chapter 16,
Section 10(3) of the Finnish Companies Act.

The grounds for the Merger and its planned timetable have been described in the
stock exchange release issued by Biotie on 27 September 2011.  The following
documents relating to the Merger are available for review on the Company's
website as of today:

(i) the Merger Plan and its appendices,

(ii) the report of Biotie's Board of Directors on the Merger,

(iii) the statement of the independent expert jointly appointed by Biotie and
Newron on the Merger,

(iv) the Company's financial statements, annual reports and auditor's reports
for the financial years 2008-2010 and its interim reports for the periods 1
January to 31 March 2011 and  1 January to 30 June 2011,

(v) Newron's financial statements, annual reports and auditor's reports for the
financial years 2008-2010 and its interim report for the period 1 January to 30
June 2011,

(vi) Minutes of the general meetings of shareholders of Biotie and Newron after
the end of the last financial period (31 December 2010),

(vii) a statement by the Board of Directors of the Company on the events that
have occurred after the interim report for the period 1 January to 30 June 2011
and that have an essential effect on the state of the Company, and

(viii) a statement by the Board of Directors of Newron on the events that have
occurred after the interim report for the period 1 January to 30 June 2011 and
that have an essential effect on the state of Newron.

In Turku, 5 October 2011

Biotie Therapies Corp.

Board of Directors

For further information, please contact:
Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8911, e-mail: virve.nurmi@biotie.com

www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media


[HUG#1552250]
Notice to Biotie shareholders on registration of merger plan and documents available for review
